These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30182454)

  • 1. UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters.
    Hermans C; Van Damme A; Dolan G; Maes P; Peerlinck K
    Haemophilia; 2018 Sep; 24(5):e378-e380. PubMed ID: 30182454
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
    Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions about the efficacy of extended half-life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States.
    Swaminathan N; Salinas-Luna V; Acharya S; Sharathkumar A
    Haemophilia; 2021 Nov; 27(6):e780-e783. PubMed ID: 34592042
    [No Abstract]   [Full Text] [Related]  

  • 9. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.
    Collins P; Chalmers E; Alamelu J; Hay C; Liesner R; Makris M; Mathias M; Payne J; Rangarajan S; Richards M; Talks K; Tunstall O; Williams M; Hart DP
    Haemophilia; 2017 Sep; 23(5):654-659. PubMed ID: 28574205
    [No Abstract]   [Full Text] [Related]  

  • 10. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.
    Keeling D; Tait C; Makris M
    Haemophilia; 2008 Jul; 14(4):671-84. PubMed ID: 18422612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic.
    Delavenne X; Dargaud Y
    Thromb Res; 2020 Aug; 192():52-60. PubMed ID: 32450448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experience in switching to new extended half-life products at European haemophilia centres.
    Peyvandi F; Garagiola I; Boscarino M; Ryan A; Hermans C; Makris M
    Haemophilia; 2019 Nov; 25(6):946-952. PubMed ID: 31418967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovations in coagulation: improved options for treatment of hemophilia A and B.
    Pabinger-Fasching I; Pipe S
    Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 19. Thirty years of haemophilia treatment in Oxford.
    Biggs R
    Br J Haematol; 1967 Jul; 13(4):452-63. PubMed ID: 6029949
    [No Abstract]   [Full Text] [Related]  

  • 20. Positioning extended half-life concentrates for future use: a practical proposal.
    Nederlof A; Mathôt RAA; Leebeek FWG; Fijnvandraat K; Fischer K; Cnossen MH;
    Haemophilia; 2018 Sep; 24(5):e369-e372. PubMed ID: 30144218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.